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Abstract Fonazepam (desmethylflunitrazepam) and nifox-
ipam (3-hydroxy-desmethylflunitrazepam) are benzodi-
azepine derivatives and active metabolites of flunitrazepam.
They recently invaded the drug arena as substances of abuse
and alerted the forensic community after being seized in
powder and tablet forms in Europe between 2014 and 2016.
A review of all the existing knowledge of fonazepam and
nifoxipam is reported, concerning their chemistry, synthesis,
pharmacology and toxicology, prevalence/use, biotransfor-
mation and their analysis in biological samples. To our
knowledge, fonazepam and nifoxipam-related intoxications,
lethal or not, have not been reported in the scientific litera-
ture. All the available information was gathered through a
detailed search of PubMed and the World Wide Web.
Keywords Fonazepam  Nifoxipam  Designer
benzodiazepines  NPS  Active metabolites of
flunitrazepam
Introduction
During recent years, a great number of new psychoactive sub-
stances (NPSs) or reappeared old ones have been introduced into
themarket of illicit drugs, and they have been reported to be used
by drug addicts. According to the European Monitoring Centre
for Drugs and Drug Addiction (EMCDDA), 101 NPSs were
detected for the first time in Europe in 2014 and 100 NPSs in
2015, and these are the highest yearly numbers recorded ever [1].
These substances usually mimic the pharmacological effects of
already known and abused drugs, possessing euphoric, stimu-
lating or hallucinogenic effects, while avoiding detection and
classification as illegal. Thus, being legally placed and generally
available in Internet shops and online sales, they often become
the causes of an increasing number of poisonings and fatal
intoxications. They also represent an enormous challenge for
clinical and forensic toxicologists, as well as policy makers in
many countries [2, 3].
A relatively new phenomenon is the occurrence of
designer benzodiazepines, like flubromazolam, meclon-
azepam, fonazepam, nifoxipam and pyrazolam, as they have
been highlighted by the EMCDDA since 2011 [4, 5]. Some
of them are common active metabolites of classic benzodi-
azepines (e.g., fonazepam), while others are prescribed
medicinal products in some countries (e.g., phenazepam) [4].
Fonazepam and nifoxipam are the desmethyl- and the
3-hydroxy-desmethyl-derivatives of flunitrazepam (one of
the 7-nitrobenzodiazepines), respectively, and they are two
of its active metabolites. Flunitrazepam has been used as a
hypnotic and pre-anesthetic drug for over 20 years, and it is
also one of the most widely abused benzodiazepines [6, 7].
Thus, these two metabolites that are also used as new
designer benzodiazepines are supposed to possess similar
pharmacological and toxicological properties to the parent
drug. Nifoxipam could also be a metabolite of fonazepam.
Fonazepam and nifoxipamhave recently invaded the drug
arena as NPSs and became known in the universal drug
community during the last 2 years. A number of nifoxipam
seizures were reported between December 2014 and July
2015 in Europe, while in the case of fonazepam, only two
recent seizures of the drug have been reported in January
2016 in Germany and in March 2016 in Sweden. These two
designer benzodiazepines are sold as research chemicals that
are not intended for human or animal consumption [8–10].
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The aim of this article is to review all the available
information on chemistry and synthesis of fonazepam and
nifoxipam, their pharmacology and toxicology, their bio-
transformation and their use as drugs of abuse, as well as the
published methods for their determination in biological
samples. All the reviewed information was gathered through
a detailed search of PubMed and theWorldWideWeb using
the keywords ‘fonazepam’, ‘nifoxipam, ‘desmethylfluni-
trazepam’, ‘3-hydroxy-desmethylflunitrazepam’, ‘pharma-
cology’, ‘determination’, ‘analysis’, ‘toxicology’,
‘intoxications’, ‘fatalities’, ‘identification’, ‘biological flu-
ids’ and ‘legal status’. Nevertheless, no data on their toxi-
cology or extended information on their prevalence were
found. Reported seizures around the world and their legal
status are also presented.
Chemistry
Fonazepam (desmethylflunitrazepam) and nifoxipam (3-
hydroxy-desmethylflunitrazepam) are two of the metabo-
lites of flunitrazepam that result from the in vivo
demethylation of the parent compound followed by 3-hy-
droxylation of the benzodiazepine ring in the case of
nifoxipam [9, 11–13]. Taking into consideration the struc-
ture of nifoxipam, we can also assume that it could be the
3-hydroxy metabolite of fonazepam. Fonazepam can also
be a photodecomposition product of flunitrazepam [14].
The IUPAC name of fonazepam is 5-(2-fluorophenyl)-7-
nitro-1,3-dihydro-1,4-benzodiazepin-2-one, while Ro-05-
4435 or Ro 5-4435, N-desmethylflunitrazepam,
desmethylflunitrazepam and norflunitrazepam are also
used. Its CAS number is 2558-30-7. Fonazepam has the
molecular formula C15H10FN3O3, a molecular weight of
299.26 g/mol, a boiling point of 470.74 C at 760 mmHg
and a melting point of 198.93 C [9, 15, 16].
The IUPAC name of nifoxipam is 5-(2-fluorophenyl)-3-
hydroxy-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one.
It is also named as 5-(2-fluorophenyl)-3-hydroxy-7-nitro-
1H-benzo[e][1, 4]diazepin-2(3H)-one, DP370 and 3-hy-
droxydesmethylflunitrazepam. Its CAS number is 74723-10-
7. Nifoxipam has the molecular formula C15H10FN3O4, a
molecularweight of 315.26 g/mol and a log P value of 10.45.
It is a crystalline solid that may bemore soluble in water than
its parent compound, due to the presence of the hydroxyl
group in the 3 position of the benzodiazepine ring. In its
powder form, it is also stable for 2 years [11, 12, 17, 18].
Synthesis
The synthesis of fonazepam was achieved in 1963 in
Hoffmann-La Roche laboratories by Sternbach et al. [19].
It was the product of the direct nitration of the
corresponding unsubstituted benzodiazepinone with a
mixture of concentrated sulfuric acid and potassium nitrate
at 45–50 C. Fonazepam is formatted in vivo via
demethylation of flunitrazepam (the parent drug), during its
biotransformation (Fig. 1), and it was identified as its
active metabolite in 1976. Nifoxipam is the product of
3-hydroxylation and demethylation of flunitrazepam
[13, 20, 21].
Prevalence and use
Fonazepam and nifoxipam are normally used in tablet
form and are administered in doses ranging from 0.5 to
3 mg [18, 22, 23]. They are also available in powder
form [18]. The most common routes of administration
are the oral and sublingual [22–24]. Users of these
designer benzodiazepines self-reported the use of other
benzodiazepines as well, like alprazolam, clonazepam,
etizolam, diazepam, lorazepam, flubromazolam or
meclonazepam [22].
Biotransformation
It is known that flunitrazepam undergoes biotransforma-
tion via N-demethylation, 3-hydroxylation and glu-
curonidation, and/or reduction of the nitro group to an
amine with subsequent acetylation (Fig. 1) [13, 20, 21].
Its formation is mediated by CYP2C19, CYP3A4 and
CYP1A2 [25–29]. Over a 7-day period, an average of
84 % of an oral dose is eliminated in urine. At least 11
metabolites of flunitrazepam have been identified in urine.
7-aminoflunitrazepam (10 % of a dose), 3-hydroxyfluni-
trazepam (3.5 %), 7-acetamidonorflunitrazepam (2.6 %)
and 3-hydroxy-7-acetamidoflunitrazepam (2.0 %) are the
major ones, while less than 0.2 % of the initial dose is
excreted unchanged [13, 20]. We can assume that fon-
azepam and nifoxipam undergo similar biotransformation
pathways (Fig. 1). There is no available information on
the biotransformation of fonazepam. On the other hand,
Meyer et al. [30] proved the metabolic pathway of
nifoxipam based on its identified urinary metabolites.
Thus, nifoxipam was mainly reduced to the respective
7-amino benzodiazepine and then acetylated (Fig. 1). The
acetylated metabolite was further conjugated with glu-
curonic acid. In that study, other metabolic steps, such as
hydroxylation or sulfate conjugation were not observed,
probably because the metabolic patterns and the
metabolites detected depend on the ingested dose and the
timespan between intake and sampling which were not
known in detail. The suggested metabolic pathway of
nifoxipam is presented in Fig. 1 [30].
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Pharmacology
Little is known about the pharmacology of fonazepam and
nifoxipam. As it has already been mentioned, they are two
active metabolites of flunitrazepam along with
7-aminoflunitrazepam (Fig. 1) and, consequently, a similar
pharmacological behavior is expected [13, 20].
Flunitrazepam is a low-dose sedative with therapeutic
doses ranging from 0.5 to 2 mg and it is used in short-term
treatment of moderate insomnia and as a premedication for
minor surgical procedures [31, 32]. Fonazepam and
nifoxipam, as benzodiazepine derivatives, probably possess
similar pharmacological activity by binding the benzodi-
azepine receptors but they are not used therapeutically.
Fig. 1 Phase I biotransformation pathways of flunitrazepam, fonazepam and nifoxipam in humans, as suggested by Wendt [20] and Meyer et al.
[30]
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More specifically, they bind with a subset of GABAA
receptors, increasing the affinity of the neurotransmitter
GABA for these receptors within the central nervous sys-
tem, exactly as flunitrazepam does [31, 33, 34] and
diminishing the transmission of several important signal
substances such as dopamine, noradrenaline, serotonin and
acetylcholine [32]. Research using neural artificial net-
works has predicted the binding affinity of fonazepam to
benzodiazepine/GABAA receptors [35]. The drug was
reported to have a binding activity (log IC50) of 0.176 and a
predicted value of 0.565 [35, 36]. Structure-activity rela-
tionship studies showed that position 7 of the benzodi-
azepine ring is the most important location on the molecule
for increasing the receptor affinity, accounting for 30 % of
the total connection weight. Increased lipophilicity and
electronic charge by the presence of the nitro group have
been directly related to increases in receptor affinity for
both fonazepam and its parent drug, flunitrazepam. The
fact that the latter possesses a higher binding activity as
well as a predicted value (0.580 and 0.778, respectively)
than its metabolite could be explained by the presence of
the methyl group on the nitrogen of the benzodiazepine
ring [35].
According to information gathered from users, the
common oral dosage of nifoxipam is between 0.5 and
1 mg, reaching 2 mg in some cases. Its onset time of action
after oral intake is 45–120 min and the duration of action is
approximately 10–75 h [17, 37]. Users report that the
intake of a 2 mg tablet of nifoxipam causes ‘‘only a small
relaxing feeling and body sedation’’, while a total dosage
of 8 mg can cause benzodiazepine-like sedation and anti-
anxiety effects along with slight euphoria and ‘‘a little
heavy’’ feeling accompanied with nightmares [22]. Other
nifoxipam users have experienced anxiety relief, greater
hypnotic action than diazepam, as well as euphoria within
10–15 min after intake of 1 mg along with a drink [23]. In
any case, euphoria and amnesia are expected effects after
their use [17]. Anticonvulsant properties of fonazepam and
nifoxipam are also expected, in part or entirely, due to
binding to voltage-dependent sodium channels rather than
benzodiazepine receptors [38].
Toxicology
To our knowledge, toxicology data on fonazepam and
nifoxipam has not been published. It is assumed that as
fonazepam and nifoxipam are active metabolites of fluni-
trazepam, they could result in respective toxicity and
adverse effects, and that their abuse could have similar
addictive potential as the parent drug.
Sedation is one of the most common physical effects of
flunitrazepam and its active metabolites. These metabolites
are moderately sedating and can potentially lead to a
lethargic state. In some cases, users experience sleep
deprivation that increases proportional to dosage and this
sense becomes eventually enough to force a person into
complete unconsciousness [17].
The predominant symptoms due to flunitrazepam over-
dose include ataxia, drowsiness, dizziness, hypotension,
muscle relaxation, respiratory depression and coma that
can be controlled successfully with supportive therapy
[17, 18, 39]. Other adverse effects are loss of motor con-
trol, lack of coordination, slurred speech, confusion and
gastrointestinal disturbances that last 12 h or more [40].
They also cause lack of coordination, which may lead to
falls and injuries, and impair psychomotor functions, such
as reaction time and driving skill with increased likelihood
of road traffic accidents [17].
Chronic use of flunitrazepam can lead to physical
dependence and appearance of withdrawal syndrome after
discontinuation. Likewise, nifoxipam is extremely physi-
cally and psychologically addictive. Within a couple of
days of continuous use, tolerance is developed along with
sedative/hypnotic effects, while after cessation, it returns to
baseline in 1–2 weeks. As with all benzodiazepines,
withdrawal or rebound symptoms may occur after ceasing
treatment abruptly following a few weeks or longer of
steady dosing, while benzodiazepine discontinuation is
difficult and potentially life-threatening for individuals that
use it regularly without progressive reduction of the
dosage. An increased risk of hypertension, seizures and
death has been reported [17, 41].
It has to be mentioned here that nifoxipam presents
cross-tolerance with all benzodiazepines, reducing in this
way their pharmacological effects [17].
The use of flunitrazepam in combination with alcohol or
opioids is always a particular concern since both of these
central nervous system depressants potentiate each other’s
toxicity [17, 42–44]. The same is expected for its active
metabolites. So, similar dangerous and potentially lethal
combinations could include the simultaneous use of fon-
azepam or nifoxipam with other depressants, dissociatives
and stimulants that usually result in fatal levels of respiratory
depression, muscle relaxation, sedation, amnesia, and vom-
iting during unconsciousness [17].
Paradoxical effects, like increased seizures in epileptics,
aggression, disinhibition, increased anxiety, irritability,
violent behavior and suicidal behavior have been described
during the therapeutic use of benzodiazepines although
they are rare with an evidence rate below 1 % [45, 46].
These effects occur with greater frequency in recreational
users, individuals with mental disorders, children and
patients on high-dosage regimens [47, 48]. Similar para-
doxical effects could be expected to appear to recreational
users of fonazepam or nifoxipam.
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Seizures
The first seizures of fonazepam were made in Europe in
2016. In January 2016, fonazepam was detected in a seized
sample of 1 g of white/yellow powder that was sent by
mail from an online chemical company based in China.
The sample was identified as fonazepam by the Medical
Center at the University of Freiburg, Institute of Forensic
Medicine, Forensic Toxicology Department in Germany
[10, 49]. Two months later, in March 2016, fonazepam was
detected in 51 tablets (27 white, 15 blue and 9 grey tablets)
seized by police in Linko¨ping, Sweden. It was confirmed
by gas chromatography–mass spectrometry (GC–MS)
using a reference standard [10, 50].
The first seizure of nifoxipam was reported in April
2014 in Visby, also in Sweden. The drug was analytically
confirmed, by the Swedish National Laboratory of Forensic
Science, as the active ingredient of 20 brown tablets seized
by the police using GC–MS, liquid chromatography–mass
spectrometry (LC–MS) and nuclear magnetic resonance
spectroscopy [12, 51]. In December 2014, four round,
light-brown tablets marked as ‘‘Nifoxipam 1 MG’’ were
sent from the UK to Finland where they were seized. The
identification of its active ingredient, nifoxipam, was per-
formed by using GC–MS and liquid chromatography–tan-
dem mass spectrometry (LC–MS/MS) [12, 52]. A month
later (January 2015), the Norwegian federal police seized
101 brown tablets found in a mail package sent from the
UK to Lørenskog, Norway. Nifoxipam was identified by
GC–MS [12, 53].
In April 2015, the Slovenian police seized a light-brown
tablet of 0.21 g and the active ingredient was confirmed to
be nifoxipam by high-performance liquid chromatography–
time-of-flight-mass spectrometry (HPLC–TOF-MS). In
May 2015, the Danish federal police seized 25 light-beige
tablets of 0.1 g that were sent from the UK to Denmark.
The tablets were seized at the Copenhagen International
Post Office and were marked by the street and chemical
name of their ingredient. The presence of nifoxipam was
analytically confirmed by GC–MS and LC–QTOF-MS
using a database [12, 54, 55]. Two more nifoxipam-related
seizures were reported in France in April and July 2015. In
the first case, 50 beige tablets sent from the UK were seized
at the airport [12, 56], while the second seizure concerned a
sample of 105 mg beige powder bought as flubromazepam
(Lexomil) [12, 57].
It seems that the problem of trafficking of these designer
benzodiazepines concerns, for the time being, only Europe,
while there is almost no information available in the USA,
Australia or Japan despite the extensive use of other ben-
zodiazepine derivatives for therapeutic or recreational
purposes at these places [4, 58, 59].
Determination of fonazepam in biological
specimens
Fonazepam and nifoxipam showed significant cross-reac-
tivity, showing a high degree of detectability for the new
designer benzodiazepines, by the most common commer-
cially available immunochemical assays for screening
purposes in urine (CEDIA, EMIT II Plus, HEIA, KIMS II)
[60, 61]. For the confirmation of the results, several ana-
lytical methods, using known chromatographic techniques,
have been developed for the determination of fonazepam as
a metabolite of flunitrazepam in biological specimens. On
the other hand, only three articles have been published that
describe analytical methods for the detection and quan-
tification of nifoxipam in biological specimens [30, 60, 61],
and in one of these studies nifoxipam was determined as
the parent drug along with its metabolites [30]. A summary
of all the developed chromatographic methods for the
determination of fonazepam and/or nifoxipam is shown in
Table 1.
Liquid-liquid extraction and solid-phase extraction
techniques have been used for the isolation of fonazepam
and nifoxipam from biological specimens. Different chro-
matographic techniques have been used for the develop-
ment of sensitive methodologies, such as GC combined
with an electron capture detector [62–65] or MS [66–69],
and LC combined with MS [70, 71], MS/MS
[30, 61, 72–76], ultraviolet detection [77, 78], diode array
detector [79] or photodiode array detection [71].
El Mahjoub and Staub [78] used an on-line column
switching HPLC method and evaluated two different
extraction columns for the determination of fonazepam as a
metabolite of flunitrazepam among other metabolites. The
procedure was based on direct injection of benzodiazepines
on the extraction column followed by the transfer of the
compounds to the analytical column.
Another sensitive analytical technique, capillary elec-
trophoresis combined with micellar electrokinetic chro-
matography, has been described by Huang et al. [80] for
the determination of fonazepam along with the other active
metabolite, 7-aminoflunitrazepam, and their parent drug,
flunitrazepam, in urine after isolation via SPE.
A nano-LC–high-resolution-MS/MS chromatographic
method was described for the identification of nifoxipam
and its phase I and II metabolites together with other new
designer benzodiazepines and their metabolites in urine.
Urine samples needed no specific preparation and they
were injected directly in the LC system for analysis [30].
No methods for the detection and determination of
fonazepam and nifoxipam in seized materials, like tablets
or powder, have been described in the literature.
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Legal status
Fonazepam and nifoxipam are newly introduced com-
pounds in some European countries. Fonazepam is a con-
trolled substance on Schedule IV of the Controlled
Substances Act in the USA as a derivative of flunitrazepam
[81]. Nifoxipam is illegal in the UK under the Psychoactive
Substance Act, which came into effect on 26 May, 2016
[11]. It has also been controlled in Denmark since 18
February 2016, after amendment of the Executive Order on
Euphoriant Substances. Thus, it may only be used for
medical or scientific purposes [12].
It is not known to be specifically illegal within other
countries around the world. However, people that possess
fonazepam and nifoxipam or intend to sell or consume
them may still be prosecuted, under certain circumstances,
by ‘‘analogue’’ laws [82].
Conclusions
Fonazepam and nifoxipam, two designer benzodiazepines,
appeared in Europe after 2014 as NPSs replacing the
known controlled benzodiazepines in the drug arena.
Although both drugs are active metabolites of fluni-
trazepam, extended information on their pharmacology and
toxicology is not available. Due to their chemical structure,
it is assumed that they possess similar pharmacological
action and toxicological behavior with the parent drug,
flunitrazepam, binding to the same GABAA receptors.
These new designer benzodiazepines are available online
labeled as a ‘‘research chemical’’ and ‘‘not intended for
human or animal consumption’’. Since they have recently
appeared in the drug arena to cover the legal loophole, the
international drug enforcement agencies are expected to
take actions and measures worldwide against their use or
abuse. Increased public vigilance by hospitals, law
enforcement and medical examiners is also needed. The
final aim is to prevent the expansion of fonazepam and
nifoxipam abuse, and the possible intoxications and deaths
related to these new designer benzodiazepines.
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